Archives

2018 TMS Research Grant Awards

Feb 12, 2018

The Mastocytosis Society, Inc. (TMS) has awarded three research grants totaling $170,000 to support research in Pediatric Mastocytosis, including Related Disorders of Pediatric Mast Cell Activation. These grants were made possible by generous donations from the Catalano Family through Wyatt’s Warriors, and from Karen and Jim Houghton. TMS congratulates our 2018 Research Grant recipients! 2018 […]

full story

TMS Research Grant Awards: 2010 – 2018

Feb 12, 2018

The Mastocytosis Society, Inc. (TMS) awards grant funding for mastocytosis and mast cell activation syndrome (MCAS) research. Below is a list of our award recipients from recent years. This page will be updated as new publications or presentations related to TMS-funded research are identified. TMS thanks all of those listed below and previous awardees for […]

full story

Olive Clayson

Jan 01, 2018

Can You Find Love and Friendship Online? Articles About Our Friend Olive… In the late 1990s, a diagnosis of mastocytosis left most with fear of the true unknown.  My family, like many others, didn’t have a personal computer in our home.  Computers were for work.  I had been unable to work for some time, but […]

full story

ICD-10-CM Codes for Mast Cell Activation Syndrome and Mastocytosis- December 2017

Dec 01, 2017

ICD-10-CM codes for Mast Cell Activation Syndrome (MCAS) were implemented in October 2016 and revised codes for Mastocytosis were implemented in October 2017! (Please visit https://www.cdc.gov/nchs/icd/icd10cm.htm for more details.) Article by: Valerie M. Slee, RN, BSN, TMS Chair Susan Jennings, PhD, TMS Research Chair ICD-10-CM Code Proposals for Mast Cell Disorders-Background Back as far as […]

full story

Dysautonomia and Mastocytosis Webinar Dec 5th

Nov 20, 2017

Join Dysautonomia International and The Mastocytosis Society on December 5, 8-9pm EST for a free online webinar reviewing the relationship between autonomic dysfunction and misbehaving mast cells. Guest speakers, Dr. Andrew White, an immunologist at the Scripps Clinic in La Jolla, California and Dr. Jonathan Bernstein, an immunologist at University of Cincinnati, will review the […]

full story

Summer 2017 Chronicles, Letter and Updates from the Chair

Jul 01, 2017

Summer Greetings! Here within TMS, there is so much going on that I hardly know where to start. The new website has been launched and running now for over four months, and we are delighted with the results thanks to the design team of Russell Hirshon and Shannon Flynn at Ministers of Design. We have […]

full story

Anaphylaxis threatens patients with systemic mastocytosis: A new study separates patients at high risk of anaphylaxis from those at low risk, a help in care

Jun 30, 2017

Anaphylaxis is a sudden, severe hypersensitivity reaction resulting from excessive release of mast cell mediators. Symptoms and signs often involve the skin. A fatal reaction may occur when the airways become obstructed or the cardiovascular system fails. Mastocytosis is characterized by an accumulation of clonal mast cells in the skin and/or internal organs. Cutaneous mastocytosis […]

full story

The Poet’s Corner

Jun 29, 2017

Welcome to The Poet’s Corner We would like to give members of our mast cell disorder community an opportunity to share their poems on this site. If you would like to submit a poem, please email it to secretary@tmsforacure.org. Ode to a Mast Cell Flare by Kathy Bell, 2016 My skin, it itches, my eyebrows, […]

full story

Rydapt© Approved for Advanced Systemic Mastocytosis Variants!

Apr 28, 2017

The Mastocytosis Society, Inc. is very excited to announce to our mast cell disorder community that the Food and Drug Administration (FDA) has approved Novartis’ drug, Rydapt©, (midostaurin, previously referred to as PKC412) for the treatment of advanced forms of systemic mastocytosis [aggressive systemic mastocytosis (ASM), SM with an associated hematologic neoplasm (SM-AHN), formerly called […]

full story

Mylan Provides Update on EpiPen® Recall

Apr 04, 2017

Mylan N.V. (NASDAQ, TASE: MYL) today announced that Meridian Medical Technologies, a Pfizer company and Mylan’s manufacturing partner for EpiPen® Auto-Injector, has expanded a voluntary recall of select lots of EpiPen (epinephrine injection, USP) and EpiPen Jr® (epinephrine injection, USP) Auto-Injectors to now include additional lots distributed in the U.S. and other markets in consultation […]

full story